Citadel Advisors LLC 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 94 0.000% | -44,534 (-99.79%) | Filing |
| 2023-02-14 08:02 am Sale | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 44,628 6.400% | -1,014 (-2.22%) | Filing |
| 2022-02-14 06:22 am Sale | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 45,642 6.500% | -791 (-1.70%) | Filing |
| 2021-07-12 4:03 pm Purchase | 2021-07-02 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 46,434 6.700% | 46,434 (New Position) | Filing |